Janux Therapeutics, Inc. (JANX)
NASDAQ: JANX · Real-Time Price · USD
17.63
+1.57 (9.78%)
Nov 6, 2026, 4:00 PM EST - Market closed
Janux Therapeutics Employees
Janux Therapeutics had 113 employees as of June 30, 2026. The number of employees increased by 10 or 9.71% compared to the same quarter last year. That makes Janux Therapeutics the 30,662nd largest employer in the world and 3,908th in the United States.
Employees
113
Change (1Y)
10
Growth (1Y)
9.71%
Revenue / Employee
$206,097
Profits / Employee
-$883,619
Market Cap
1.08B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Jun 30, 2026 | 113 | 10 | 9.71% |
| Mar 31, 2026 | 108 | 17 | 18.68% |
| Dec 31, 2025 | 109 | 28 | 34.57% |
| Sep 30, 2025 | 109 | 33 | 43.42% |
| Jun 30, 2025 | 103 | 34 | 49.28% |
| Mar 31, 2025 | 91 | 23 | 33.82% |
| Dec 31, 2024 | 81 | 17 | 26.56% |
| Sep 30, 2024 | 76 | 12 | 18.75% |
| Jun 30, 2024 | 69 | 2 | 2.99% |
| Mar 31, 2024 | 68 | 6 | 9.68% |
| Dec 31, 2023 | 64 | 4 | 6.67% |
| Sep 30, 2023 | 64 | 8 | 14.29% |
| Jun 30, 2023 | 67 | 18 | 36.73% |
| Mar 31, 2023 | 62 | 21 | 51.22% |
| Dec 31, 2022 | 60 | 27 | 81.82% |
| Sep 30, 2022 | 56 | 28 | 100.00% |
| Jun 30, 2022 | 49 | 27 | 122.73% |
| Mar 31, 2022 | 41 | 25 | 156.25% |
| Dec 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| UroGen Pharma | 300 |
| Omeros | 175 |
| MoonLake Immunotherapeutics | 130 |
| Verastem | 102 |
| Silence Therapeutics | 88 |
| Vor Biopharma | 76 |
| SpyGlass Pharma | 76 |
| Savara | 70 |
JANX News
- 2 days ago - Janux Therapeutics price target raised to $40 from $36 at Wedbush - TheFly
- 2 days ago - Janux Therapeutics price target raised to $23 from $22 at BofA - TheFly
- 2 days ago - Janux Therapeutics price target lowered to $34 from $35 at Stifel - TheFly
- 2 days ago - Janux Therapeutics price target raised to $15 from $14 at Barclays - TheFly
- 3 days ago - Janux Therapeutics reports Q3 EPS (34c), consensus (49c) - TheFly
- 3 days ago - Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights - Business Wire
- 3 days ago - Janux Therapeutics Earnings release: Q3 2026 - Filings
- 3 days ago - Janux Therapeutics Quarterly report: Q3 2026 - Filings